Evidence map›Paper›PMID 38879744›Full record

ArticleAmerican journal of epidemiology2024

Learning optimal dynamic treatment regimes from longitudinal data.

Nicholas T Williams, Katherine L Hoffman, Iván Díaz, Kara E Rudolph

Abstract read
In one paragraph

Article in American journal of epidemiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nicholas T WilliamsDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, United States.ORCID 0000-0002-1378-4831
Katherine L HoffmanDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, United States.ORCID 0000-0003-3392-3541
Iván DíazDivision of Biostatistics, Department of Population Health Sciences, Grossman School of Medicine, New York University, New York, NY 10016, United States.
Kara E RudolphDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, United States.ORCID 0000-0002-9417-7960

Funding

The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials NetworkUG1DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Daniel J Feaster, Viviana Elizabeth Horigian · 2015 to 2026
$50.6M
Training Program on HIV and Substance Use in the Criminal Justice SystemT32DA037801 · NIDA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Nabila El-Bassel, Lisa R Metsch · 2014 to 2026
$5.7M
Design and analysis advances to improve generalizability of clinical trials for treating opioid use disorderR01DA056407 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Kara Elizabeth Rudolph, Elizabeth A. Stuart · 2022 to 2026
$3.1M
NIDA NIH HHS R01 DA056407NIDA NIH HHS T32 DA037801NIDA NIH HHS UG1 DA013720
6 · The paper itself

Abstract

Investigators often report estimates of the average treatment effect (ATE). While the ATE summarizes the effect of a treatment on average, it does not provide any information about the effect of treatment within any individual. A treatment strategy that uses an individual's information to tailor treatment to maximize benefit is known as an optimal dynamic treatment rule (ODTR). Treatment, however, is typically not limited to a single point in time; consequently, learning an optimal rule for a time-varying treatment may involve not just learning the extent to which the comparative treatments' benefits vary across the characteristics of individuals, but also learning the extent to which the comparative treatments' benefits vary as relevant circumstances evolve within an individual. The goal of this paper is to provide a tutorial for estimating ODTR from longitudinal observational and clinical trial data for applied researchers. We describe an approach that uses a doubly robust unbiased transformation of the conditional ATE. We then learn a time-varying ODTR for when to increase buprenorphine-naloxone dose to minimize a return to regular opioid use among patients with opioid use disorder. Our analysis highlights the utility of ODTRs in the context of sequential decision-making: The learned ODTR outperforms a clinically defined strategy. This article is part of a Special Collection on Pharmacoepidemiology.

Indexed as

BuprenorphineNaloxoneOpioid-Related DisordersHumansLongitudinal StudiesNarcotic AntagonistsOpiate Substitution TreatmentBuprenorphineNaloxoneNarcotic Antagonistscausal inferencedoubly robust methodslongitudinal studiesoptimal treatment rulesprecision medicine

Identifiers

PMID38879744
PMCPMC11637529

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.